CYTALUX

Peak

pafolacianine injection

NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100

Mechanism of Action

12.1 Mechanism of Action Pafolacianine binds to alpha and beta folate receptors (FR) on cells, is internalized via receptor-mediated endocytosis, and accumulates intracellularly. Pafolacianine enhances lesion visualization through the differential level of expression and accessibility of folate…

Indications (1)

Loss of Exclusivity

LOE Date
Oct 4, 2033
92 months away
Patent Expiry
Oct 4, 2033
Exclusivity Expiry
Nov 29, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
10881747
Aug 26, 2033
SubstanceProduct
U-3291
9061057
Aug 26, 2033
SubstanceProduct
U-3291
9333270
Aug 26, 2033
SubstanceProduct
U-3291
9341629
Aug 26, 2033
SubstanceProduct
9789208
Aug 26, 2033
SubstanceProduct
U-3291